|Bid||39.00 x 2200|
|Ask||39.00 x 800|
|Day's Range||38.62 - 39.29|
|52 Week Range||32.88 - 48.37|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||23.67|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||1.52 (2.85%)|
|1y Target Est||45.25|
shares were declining 1.07% in trading Thursday after the company said that its first-quarter guidance cut last month was due to the effects of flooding in the Midwest that caused transportation disruptions and halted farming operations in its agriculture business.
Tapping into this national mood, some policy makers have proposed stronger antitrust enforcement, breaking up big tech companies, and applying closer scrutiny to M&A deals. Normally, businesses in the same industry compete with each other in order to maximize their own market share. If one of these firms cuts prices and increases its market share at its rivals’ expense, any resultant gain for the firm’s stockholders will be roughly matched by the losses at the competing firms that the stockholder also holds.
DowDuPont Inc. said Thursday it expects its agriculture business to fall short of guidance for the first quarter after severe weather delayed seed deliveries into early April. "Less than 50% of planned seed deliveries in the last 5 days of the quarter occurred, resulting in a greater than anticipated impact on first quarter performance," the company said in a statement. "In this peak delivery period, under normal circumstances and based on history, the division would expect one day of U.S. seed sales to generate about $25 to $35 million in operating EBITDA." The division is now expected to record sales of $3.4 billion and operating EBITDA of about $665 million, down 11% and 25% versus the year-ago period, respectively. For the first half, the division is expecting sales to be down in the low-single digit percent and operating EBITDA to be 3% to 5% below the year-ago period. "Deliveries are on track with current expectations and the revised first half guidance reflects the possibility of reduced planted acres overall, lower than anticipated corn acres, and continued delays to the start of the planting season due to additional weather events," said the statement. The company is sticking with its full-year guidance for sales and operating EBITDA, and expects to overcome the first-half decline through price increases and new product launches, among other factors. Turning to its other businesses, DowDuPont is expecting specialty products to post sales of $5.4 billion, down 3% from a year ago, and operating EBITDA of $1.6 billion, flat versus the year-earlier period. That compares with earlier guidance of net sales and operating EBITDA to be down in the low-single digits. Materials science is expected to post sales of $10.8 billion and operating EBITDA of $1.9 billion, down 10% and 24% respectively. That is in line with previous guidance. Shares fell 0.5% premarket and are down 14.3% in the last 12 months, while the S&P 500 has gained 7.1%.
WILMINGTON, Del., April 18, 2019 /PRNewswire/ -- DowDuPont™ (DWDP) is providing expected divisional results for the first quarter of 2019. Agriculture: On March 28, the Agriculture Division reported on the effects of March flooding in the Midwestern U.S., which created transportation disruptions that halted farming operations and severely delayed seed deliveries into the early part of April. In this peak delivery period, under normal circumstances and based on history, the division would expect one day of U.S. seed sales to generate about ~$25 to $35 million in operating EBITDA.
If you're looking for an honest read on the economy, look no further than the rails, Jim Cramer reminded his Mad Money viewers Wednesday. and Cramer showed viewers how this one earnings report can be used to read the entire economy. All of the money to buy these stocks needs to come from somewhere, Cramer added, and right now money managers are selling healthcare.
Many people rely on government data, such as information from the Commerce Department or the Fed. In fact, go back to when Jerome Powell created his own darned bear market back in October of 2018. Powell was gung ho on one rate raise in December and three more this year because he feared runaway inflation.
"If you want to get an honest read on the economy, forget the government data from the Commerce Department," CNBC's Jim Cramer says. "It's such a terrific tell for what's happening in the U.S. economy, and it's also fabulous source of inspiration if you're on the hunt for new stock picks," he says. CSX Transportation CSX 's Tuesday earnings call gave some insight into what stocks could be worth playing, CNBC's Jim Cramer said Wednesday.
WILMINGTON, Del., April 17, 2019 /PRNewswire/ -- DowDuPont (DWDP) today announced three additional members to the future board of directors of DuPont, currently the Specialty Products Division of DowDuPont. The new directors include Frank K. Clyburn, chief commercial officer at Merck & Co., Inc., Terrence R. Curtin, CEO of TE Connectivity, and Frederick M. Lowery, senior vice president and president, Life Sciences Solutions and Laboratory Products at Thermo Fisher Scientific Inc. With these additions, DuPont expects to have 12 members on its board, effective June 1, 2019.
It has been relentless, everything from airlines pulling orders to stories in the paper about how the FAA is over-reliant on Boeing for approvals. Boeing's stock barely gets dented with orders cancelled or changed. When airline cancels routes - and therefore causes it to lose money because of the Max -Boeing's stock barely gets dented.
While RBC Capital Markets is bullish on the new company split off from an old chemicals name, it's less positive on what remains of the old business. The Analyst Arun Viswanathan initiated coverage of ...
Another day, another Dow stock upgrade. Analysts continue to prefer Dow shares to DowDuPont stock, even though both face macroeconomic risks.
JPMorgan stock and Disney stock helped fuel a nice rally in the Dow Jones today, while Jumia Technologies had a strong IPO debut.
Bloomberg reports a synthetic replication of a indigestible sugar in breast milk could help adults' digestion.
Global chemical giants DowDuPont Inc. and BASF SE are investing millions to ramp up production of an indigestible sugar found naturally in breast milk. Infant formula makers like Nestle SA can’t get enough of the synthetic ingredient. DuPont estimates the annual market could reach $1 billion.
Shares of the now-independent Dow Inc (NYSE:DOW) declined on Friday for the first time since the company was spun off . The Midland, Michigan-based manufacturer of chemicals saw its stock fall on a bearish initiation by an analyst. After Dow Inc stock rose for three straight days, investors may have had good reasons to doubt the shares.Source: Shutterstock But investors should remember that the initiation contrasts with the analyses of numerous others on the Street. And while it remains unclear how the bearish evaluation will affect DOW stock in the longer run, the note should remind investors to compare Dow Inc stock to its peers. The InitiationDow Inc stock fell by $2.47 per share to $57.24 per share on Friday, representing a 4.14% decline for the day. At that point, Dow stock had only traded four days since completing its spinoff from DowDuPont (NYSE:DWDP).InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Dow Jones Stocks Holding the Blue Chip Index Back Shares fell after JPMorgan analyst Jeffrey Zekauskas started Dow Inc stock with an "underweight" rating. He set a $49 price target on Dow Inc stock, which would represent a discount of around 12.5% from its current levels. The stock has now received a rating from 17 analysts, and Zekauskas became the first analyst to make a bearish call on DOW stock.In his report, he noted that DOW has a higher dividend than its peers. According to Zekauskas, DOW's 2019 dividend will be equal to 25% of its EBITDA. That implies a yield of about 4.7%. Dow's peers, LyondellBasell Industries (NYSE:LYB) and Westlake Chemical (NYSE:WLK), have lower yields, he wrote. Dow Inc Stock Trades at a Higher Multiple Than Its PeersIt remains unclear whether Dow Inc stock will fall to the $49-per-share level. Still, Zekaukas makes some important points in his report. The forward earnings multiple of Dow Inc stock, based on analysts' average 2019 EPS estimate, is 9.9. LYB stock trades at around 7.8 times its estimated forward earnings, while the forward PE of WLK stock stands at about 8.9.Moreover, Dow Inc stock has returned to trading as an independent company after briefly teaming up with DuPont. At this point, I think traders need more time to fully assess DOW stock. Dividend DangersTraders might overlook these concerns due to Dow's high dividend yield. Unfortunately, investors have good reason to hold doubts about the payout.DowDuPont slashed its dividends in 2017 and 2018 after increasing them annually for years. Conversely, after Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) broke up, they continued their decades-long tradition of yearly payout hikes. As a result , Dow Inc stock will not have a "dividend aristocrat" streak (meaning 25 or more years of annual dividend increases) that it can use to attract investors.For this reason, investors in the chemicals space might see better returns from LyondellBasell stock. LYB trades at a substantially lower forward PE ratio than Dow Inc stock. And despite the fact that LYB's 4.4% dividend yield is slightly lower than that of DOW, LYB has increased its annual payouts for seven straight years. So the outlook of LYB stock's dividends is more certain at this time. Concluding Thoughts on Dow Inc StockThe analyst's initiation has reminded investors to compare Dow Inc stock to its peers before buying DOW stock. But Zekauskas' bearish initiation goes against the grain. For this reason, investors should not simply assume that DOW will fall to $49 per share.However, the analyst argument that DOW may not compare well to its peers is solid. Moreover, DOW stock has only traded for a few days since it again became an independent company. Investors may need more time to develop a deeper understanding of DOW stock before buying the shares. Until the path pf Dow Inc stock becomes clearer, investors should probably look to other equities in the chemicals space.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post Analyst Note Fosters Doubts About Dow Inc Stock appeared first on InvestorPlace.
It has been a pretty good year for the market, although not uniformly. While some stocks are roaring, others are struggling. A handful of the 30 Dow Jones stocks, in fact, are proving to be downright liabilities in an environment that has been largely bullish. While the Nasdaq is up nearly 20% year-to-date and the S&P 500 is higher by 15.5%, the value of the Dow Jones today leaves it lucky to be up 12.9% since the last trading day of December.A relatively small handful of names are to blame, weighing the blue chip index down arguably more than it deserves. * 8 Risky Stocks to Watch as Earnings Season Kicks Off To that end, here's a rundown of the 10 Dow Jones stocks doing the most harm to the old-school index. In some cases these names may be ripe for a turnaround. In others, their current weakness may be a microcosm of what's to come. Tread lightly and thoughtfully if you wade into any of these picks on their recent softness.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dow Jones Stocks: Walmart (WMT)YTD Gain: 6.5%Source: Shutterstock Walmart (NYSE:WMT) may be the king of brick-and-mortar retailing, and it has finally figured out how to compete with Amazon.com (NASDAQ:AMZN) on the e-commerce front. Last quarter's online sales grew 43% year-over-year, extending a long-standing streak of double-digit improvement.The market has stopped rewarding the company for its progress, though.Reasons for the pause are debatable, but most investors are concerned about their sheer number. They include worries like Amazon's foray into the grocery store business, a wage war with rival Target (NYSE:TGT) and the lingering impact of a tariff war with China. It's a lot, collectively, to overcome. DowDuPont (DWDP)YTD Gain: 7.5%Source: Shutterstock The spinoff of Dow (NYSE:DOW) from former parent DowDuPont (NYSE:DWDP) was a well-received idea, as was the spinoff of agrochemical business Corteva.While complex conglomerates at one time made for powerhouse companies, now they're liabilities. Smaller is better because it facilitates nimbleness. Splitting operations out into their respective business not only unlocks hidden value, it lets investors enjoy more choice as to the kind of stock they want to own. * 7 High-Risk Stocks With Big Potential Rewards And, as it turns out, DowDuPont has been pegged as the weak link, by analysts as well as by investors willing to follow analysts' lead. It's up a little for the year, but even on a split-adjusted basis it is still down 27% from its early 2018 high. Merck (MRK)YTD Gain: 5.9%Source: Shutterstock To be fair, Merck (NYSE:MRK) may largely be a victim of its own success. MRK stock gained 36% over the course of 2018, and got 2019 started on a bullish foot as well. Its cancer therapy Keytruda is proving potent on more and more fronts, winning approval as a first-line option in China as a treatment for lung cancer just last week.The sheer weight of the gains, however, may simply be too much to overcome. The full potential of Keytruda may already be factored into the price of MRK stock, and then some.Underscoring the bearish argument is the recent, and relatively small, deal to acquire Immune Design for $300 million and the equally recent decision to issue $5 billion in bonds. It's not clear why Merck needs to take on debt -- as cheap as it may be -- and the interest in a small deal like Immune Design, which has struggled with R&D of late, implies the company may be struggling to refill its pipeline with compelling candidates. Johnson & Johnson (JNJ)YTD Gain: 6.5%Source: Shutterstock Rival drugmaker Johnson & Johnson (NYSE:JNJ) has fared a little worse than Merck, up only 6.5% since the end of 2017. The reasons for its weakness, however, are notably difference.Chief among its headwinds is ongoing legal wrangling with a group that claims they were adversely impacted by asbestos found in the company's talcum powder years ago. Even if the fiscal liability is tamped down (and it mostly has been), the company's reputation has been dented in the court of public opinion. J&J is also now being targeted as a key cause of the nation's opioid epidemic. The implications of that matter are not yet clear, but none of them help boost the value of JNJ stock. * 10 Medical Marijuana Stocks to Cure Your Portfolio In the meantime, the failure of its baby shampoo to pass a quality test administered in India readily reprises consumers' and investors' concerns. Verizon Communications (VZ)YTD Gain: 5.3%Source: Shutterstock Verizon Communications (NYSE:VZ) was a champ in 2018, working its way out of a multiyear rut to make a move to multiyear highs. Fanning those flames is the fact that it led its peers in the race to 5G connectivity, unveiling its first ultra-high-speed internet connections to homes, without the use of actual wires to the home. The underlying hardware may not be compliant with the industry standard that's been agreed upon by companies developing the hardware to make 5G readily available everywhere, but clearly Verizon is setting the pace.Investors haven't been as keen on Verizon's 5G opportunity so far this year though, perhaps realizing there's still so much heavy lifting to do before it impacts the top or bottom line.In the meantime, investors are increasingly wondering if the company's decision to double-down on web presences like Yahoo and AOL were misguided. At the end of last year the company booked a $4.6 billion charge essentially because each arm of its Oath unit have failed to live up to expectations. And, things may get worse before they get better for AOL and Yahoo. Walt Disney (DIS)YTD Gain: 4.8%Source: Shutterstock Not only are Walt Disney (NYSE:DIS) shares up a scant 4.8% since the end of 2018, they're trading right where they were in July of 2015, as investors question the strength of its future.The reboot of Star Wars movies, the steady flow of Marvel movies that will wind down a story line that consists of more than 20 films and the acquisition of most of Fox was supposed to serve as a growth engine for years to come. Broadly speaking though, every new profit center Disney has put in place has been offset by headwinds on other front. Disney is struggling on the small screen, competing with a very formidable Netflix (NASDAQ:NFLX) while it fights a losing battle with its ESPN property. * 7 Biometric Stocks to Watch as AI Rises The company is hardly on its last legs. Indeed, it can be reinvigorated with the right tweaks. Investors, however, are still waiting to see what Disney can do through 2019 and beyond. UnitedHealth Group (UNH)YTD Gain: 1%Source: Shutterstock Although it arguably wasn't supposed to, healthy insurer UnitedHealth Group (NYSE:UNH) found a way to become a growth machine in the volatility that was borne from the launch of Obamacare, and then the 2017 cancellation of it. UNH stock soared more than 400% between late 2012 and late 2018, reflecting steady sales and earnings growth.There are limits though, and UnitedHealth may have reached its technical extreme. From here it needs a good capitulation before it can renew the bigger-picture uptrend.Underscoring the market's worries is sheer uncertainty. Clearly President Donald Trump wants to do something with healthcare, but doesn't even want to detail his plans until after the election. Adding to that uncertainty is the chance he won't be re-elected at all, putting the future of healthcare in the hands of just-as-undecided Democrats. Pfizer (PFE)YTD Gain: -0.5%Source: Shutterstock Johnson & Johnson and Merck may be a couple of poorly performing Dow Jones stocks from the same industry, but their rival Pfizer (NYSE:PFE) is doing notably worse. It's off 0.5% year-to-date, and toying with a move to lower lows.Pfizer is facing the same basic challenges Merck and J&J are … pipeline or acquisitions? What liabilities lie ahead, particularly if the regulatory landscape of medicine changes? Where is its current portfolio vulnerable, particular to generics and biosimilars? * 8 Stocks to Buy for Massive Outperformance Pfizer has arguably missed the mark in answering those questions well enough for investors though. That's unfortunate -- and perhaps a bit unfair too -- as Lyrica, Ibrance and Prevnar are proving to be real powerhouses that could carry the company to and through the development of new drugs and even fully fund dealmaking. Coca-Cola (KO)YTD Gain: -1.5%Source: Leo Hidalgo via Flickr (Modified)Coca-Cola (NYSE:KO) is a perennial, long-term winner for those who are willing and able to hold it for periods measured in years. In the interim though, sizable pullbacks are the norm. It's off 1.5% year-to-date, though down 8% from November's highs (yet up 4.5% from March's low).The swings mostly reflect investors' ever-changing opinion of how Coke is dealing with multiple challenges. Between tariffs, currency volatility, healthier-thinking consumers and new niche competition, the bullish argument for KO stock hasn't always been a consistent one.Perhaps more than anything right now, however, KO stock is being held back by an unpalatable valuation. Priced at more than 21 times the coming year's expected earnings but only projected to grow the top line at 5.5% this year, there are many, far better prospects. Walgreens Boots Alliance (WBA)YTD Gain: -19.5%Source: Mike Mozart via FlickrFinally, Walgreens Boots Alliance (NASDAQ:WBA) is the bottom-dweller in terms of this year's performance among Dow Jones stocks. It's down 19.5% year-to-date, though that figure actually understates its recent performance. WBA stock has actually fallen 35% from November's high.The latest leg of the setback was inspired by a disappointing quarterly report. The stock fell more than 12% on April 2 when the company posted earnings of $1.64 per share versus expectations of $1.74. That tumble was only an extension of the selloff that took shape three months earlier though, which got rolling despite a decent quarterly print. * 8 Risky Stocks to Watch as Earnings Season Kicks Off That's when the drugstore chain unveiled a major cost-cutting initiative that confirmed competition was mounting, offline as well as online.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post 10 Dow Jones Stocks Holding the Blue Chip Index Back appeared first on InvestorPlace.
Most Wall Street analysts updating their ratings and financial models following the DowDuPont split tend to favor the new Dow stock over DowDuPont.
closed down 4.14% to $57.24 Friday, after JPMorgan initiated coverage of the materials science company with an underweight rating and a target price of $49. Zekauskas said he believes the market has yet to see the low point of domestic ethylene and polyethylene margins for 2019-2020, and adds that Dow's earnings and trading multiples are sensitive to oil prices. "The risk to the Dow share price is, for this reason, larger than that of the price risk of the other petrochemical companies as Dow could well lose the dividend premium it receives currently," he said.
Jim Cramer breaks down the latest action on Wall street and explains why certain stocks have risen when analysts said they would fall.